Two Sigma Securities’s CytoMed Therapeutics GDTC Stock Holding History

Two Sigma Securities’s Portfolio GDTC Stock Details GDTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,857	Closed	-$15.8K	–	1831
2025 Q4	$15.8K	Buy	+11,857	New	+$23K	﹤0.01%	1216

Other funds holding GDTC

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Securities's GDTC Position: Q1 2026 in Review

Two Sigma Securities sold out of CytoMed Therapeutics (GDTC) in Q1 2026, closing a stake of 11,857 shares — an estimated $15.8K sold.

Two Sigma Securities first reported a position in GDTC in Q4 2025 and held it in 1 quarter. The position peaked at $15.8K in Q4 2025. 3 funds tracked by Wall St. Rank hold GDTC as of Q1 2026.

Two Sigma Securities reported no remaining CytoMed Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 11,857 CytoMed Therapeutics shares in Q1 2026, an estimated $15.8K.
Two Sigma Securities first reported a position in CytoMed Therapeutics in Q4 2025 and held it in 1 quarter.
Two Sigma Securities's CytoMed Therapeutics position peaked at $15.8K in Q4 2025.
3 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.